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Abstract
Though the advantages of routine virological monitoring for patients on anti-retroviral therapy have been established, cost and
complexity limit its full implementation. Monitoring is important for diagnosing virological failure early on, before the
development of drug resistance mutations, and to trigger early adherence interventions. Simple and cost-effective viral load
tests that facilitate simplification and decentralization of testing and strategies, such as the use of dried blood spots and pooled
sample testing, which further aid simplification, are becoming available. In addition, replacing immunological monitoring with
virological monitoring in non-viremic patients in a phased manner will reduce the costs associated with dual immuno-virological
monitoring. Going forward, the simplification of testing paired with price reducing strategies that will allow for healthy
competition between multiple manufacturers will enable the implementation of viral load testing in resource-poor settings. It is
important that future HIV and AIDS treatment guidelines provide clear recommendations for routine virological monitoring and
that governments and donors fund the implementation of accurate and operationally proven testing platforms in a
comprehensive manner.
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Introduction
The benefits of virological monitoring for patients on anti-
retroviral therapy (ART) are well established and include the
ability to diagnose adherence problems and treatment
failure, and optimize therapy to support reduced transmis-
sion [13]. However, there are a number of access barriers to
viral load in resource-limited settings, including high cost,
technical complexity and difficulties with sample transport
from the periphery and quality control. The result is that,
while viral load testing is the standard of care for patients in
rich countries, routine virological monitoring is rarely avail-
able in most high-HIV prevalence settings. A recent survey
across 23 low-resource countries revealed that national
virological testing was available only for confirmation of
treatment failure in Kenya and for routine treatment
monitoring in Brazil, Botswana and South Africa [4].
Evidence of the benefit of viral load monitoring at the
population level is mixed. Trials evaluating the short-term
benefit of virological monitoring against clinical endpoints,
which are considered delayed outcomes, have concluded no
major benefit over-and-above clinico-immunological moni-
toring [57]. However, longer term observational studies
have shown that clinico-immunological monitoring is inaccu-
rate [3,810]. Furthermore, while it is well accepted that
mortality follows a CD4 decline on treatment [11], both
viremia copy-years and cross-sectional virological measure-
ments can independently predict all-cause mortality as
well [12]. Support for simpler, more affordable and more
cost-effective technologies is growing [213], partly fuelled
by a growing concern that unchecked viremia could lead to
the development and transmission of drug resistance [14,15].
Recognizing these multiple benefits, the latest World
Health Organization (WHO) guidelines for ART in resource-
limited settings, issued in 2010, recommend that all countries
begin to phase-in viral load monitoring.This viewpoint article
provides an overview of current implementation barriers to
viral load testing in resource-limited settings and provides
some practical recommendations for increasing capacity for
routine virological monitoring in low- and middle-income
countries.
Importance of routine virological monitoring
Diagnose early virological failure on ART
Effective treatment should suppress viral replication. A meas-
urable viral load is, therefore, a very accurate measure of
unsuccessful treatment. The WHO defines virological failure
as a viral load above 5000 copies/ml and recommends
that virological monitoring be performed biannually [16].
Frequent monitoring enables the diagnosis of virological
failure before the development of drug resistance mutations,
which would ultimately lead to treatment failure and allow
for possible viral transmission [17].
In the absence of virological monitoring, immunological
monitoring by CD4 count change is recommended. WHO
guidelines define immunological failure as a CD4 count
falling to or below the baseline value, or a 50% fall from the
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1on-treatment peak or persistent CD4 values below 100 cells/
ml [16]. However, CD4 testing has a poor accuracy and low
positive predictive value in both adults [10,18] and children
[8] for diagnosing treatment failure. Thus, viral load remains
the gold standard.
Discriminate between poor adherence and treatment
failure
Unsuccessful treatment, leading to virological failure, may be
due to a number of reasons, including drug interactions,
malabsorption and poor adherence [1921]. While viral
load has been seen as a tool to diagnose failure, the main
benefit is the prevention of treatment failure by identifying
patients in need of intensive adherence counselling. The
WHO guidelines define treatment failure as persistent
virological failure [16], the first episode of virological failure
typically being followed by a period of intensive adherence
counselling and support, followed by a second viral load.
If virological failure persists, and there has not been a
significant ( 0.5 log) drop in viral load, treatment failure is
diagnosed, with a consequential regimen switch. However,
published data indicate that, in the majority of cases, viral
suppression is achieved after intensive adherence counselling
[2023]. Early good adherence is predictive of long-term
virological suppression [20], and there is some evidence that
virological monitoring, if done soon after treatment initiation
(i.e. at three months) leads to better outcomes by flagging
those patients in need of adherence counselling [24].
Once non-adherence has been ruled out, persistent
viremia indicates treatment failure and the need for an
appropriate treatment switch. According to WHO guidelines,
a persistent viral load above 5000 copies/ml confirms
treatment failure [16], although some countries, such as
South Africa and Zambia, have adopted a lower-level
threshold of 1000 copies/ml [10,17]. Drug resistance occurs
when patients are kept on failing regimens at virological
levels above 1000 copies/ml, limiting future treatment
options [25]. European guidelines recommend that an ARV
drug resistance test be performed at a viral load above
500 to 1000 copies/ml [26]; however, data from a European
multicentre cohort study showed that 15.14% of test
results were obtained at viral loads B1000 copies/ml and
that, while the probability of mutations occurring below
500 copies/ml was lower, their presence might indicate
the emergence of drug resistance and allow for an earlier
preventative intervention [27]. Guideline revisions to favour
lower thresholds may therefore be necessary.
Importantly, the poor accuracy and positive predictive
value of clinico-immunological monitoring compared to
virological monitoring for predicting treatment failure means
that, without viral load testing, patients are either diagnosed
very late or misdiagnosed completely, with the result
that patients can be kept on a failing regimen or switched
unnecessarily. Furthermore, when clinico-immunological cri-
teria are used to diagnose treatment failure, extensive drug
resistance occurs, limiting the use of future treatment
options [28,29]. Virological monitoring is therefore necessary
for the confirmation of both clinical and immunological
failure and should ideally be used for the timely diagnosis
of treatment failure, before clinical or immunological
deterioration [10,18,30].
Support treatment monitoring and optimization
The superiority of virological monitoring over clinico-
immunological monitoring for diagnosing virological failure
has multiple benefits beyond the initiation of adherence
interventions and the appropriate switching of treatment
regimens. Reducing the risk of virological failure through
targeted adherence counselling and support prevents the
development of drug resistance mutations, leading to the
preserved use of affordable, fixed-dose, first-line drugs [1,31].
The benefit of using the diagnosis of virological failure as a
means to intervene and prevent disease progression early
has been shown in studies which found that patients without
access to annual virological monitoring have poorer out-
comes [32]. Virological monitoring can serve as an indepen-
dent predictor of AIDS-defining events and mortality, even at
CD4 counts above 350 cells/ml [3335]. In some Western
settings, it is recommended that patients are initiated on ART
at high viral loads (above 100,000 copies/ml), regardless of
CD4 count [26].
Simplification of ART delivery
To scale up treatment to the millions of people in need, ART
delivery needs to be made as simple as possible, in line with
the public health approach to HIV treatment and care
promoted by the WHO. The management of treatment
failure is one area where simplification is becoming increas-
ingly urgent. Detection of treatment failure using standard
immunological definitions is poorly implemented in resource-
limited settings. Only 1.6% of patients receiving treatment as
part of HIV programmes supported by Me ´decins Sans
Frontie `res (MSF) in 19 countries have been switched to
second-line therapy, suggesting very poor levels of detection
[36]. Calculating CD4 changes over time from paper records
is a challenge for clinicians, especially in overburdened
clinics. In contrast, routine virological monitoring provides a
useful cross-sectional measurement of treatment efficacy,
reducing the necessity to review historic data and facilitating
appropriate clinical interventions (such as adherence coun-
selling or regimen switching).
Having a test that clearly confirms virological suppression
may also allow for less frequent clinical follow-up and further
task shifting. Simplification of treatment monitoring using an
annual clinical visit with review of the viral load could
significantly reduce the number of clinical contacts required,
having both a cost-saving effect and reducing the burden on
patients and healthcare workers alike.
Options for increasing access to
virological testing
Types of tests
An overview of current and pipeline tests for viral load has
been provided elsewhere [37].
Molecular versus non-molecular testing
Viral load assays have traditionally been based on the
amplification of nucleic acid using molecular techniques,
such as real-time polymerase chain reaction (PCR). However,
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2contamination with foreign nucleic acid or amplicon (PCR
products) can cause false positive results, and great care
must be taken to avoid cross-contamination of samples
[38,39]. Moreover, precision pipetting is required to achieve
an accurate result. One way to limit contamination and
pipetting errors is to automate the process as far as possible,
which is feasible with currently available technologies for
sample preparation and subsequent amplification and detec-
tion. PCR products should be contained and disposed of or
safely stored directly after the amplification and detection
stage [40].
As an alternative, a non-molecular test, such as the ExaVir
Load Assay (Cavidi, Uppsala, Sweden), may be used. This
method relies on the detection of reverse transcriptase as a
surrogate marker for HIV RNA using an ELISA-type technique
routinely used even at district laboratory level [38]. A major
advantage is that the enzyme is conserved across HIV-1
strains and is therefore subtype independent [41]. While
inexpensive and easy to perform, this assay has a number of
disadvantages, including the use of plasma as a sample type,
lower through-put (the test takes two days to perform and a
technician can only process a maximum of 180 samples/week
compared to four hours processing and 800 samples/week
for molecular tests); no automation, resulting in demand for
hands-on time; and the inability of the manufacturer to
supply controls (known HIV-positive and HIV-negative plasma
must be supplied on-site for this purpose) [38,42].
Viral load may also be measured by quantifying the
concentration of p24 antigen. This non-molecular test is
cheaper and simpler than a test for HIV RNA [41]. While the
WHO recommends the use of ultrasensitive p24 testing
for early infant diagnosis, it is not considered sufficiently
sensitive to serve as a treatment monitoring tool [38,43].
A further disadvantage is that there is only one test available
for the ultrasensitive measurement of p24, manufactured by
PerkinElmer (Waltham, USA), although it is not commercia-
lized and may only be used for research purposes [37]. Given
that the concentration of p24 has been found to correlate
with HIV RNA and predicts clinical stages and mortality [44],
further research into the use of p24 for treatment-monitor-
ing purposes may be warranted in areas where HIV RNA
testing is not available due to resource constraints.
Laboratory-based tests versus point-of-care devices
MSF has set up a molecular laboratory at the district level in
Thyolo, Malawi, to offer viral load testing using the NucliSENS
EasyQ HIV-1 v2.0 assay (bioMe ´rieux, Marcy-l’E ´toile, France).
The NASBA-based technique was chosen due to the fact that
the test has been validated on dried blood spots (DBS)
[45,46], which was the chosen sample type. A number of
logistical challenges were encountered during the setting up
of this laboratory, including unsuitable laboratory infrastruc-
ture; unreliable power supply; unreliable water supply and
provision of RNAse-free water; unreliable air-conditioning;
non-adherence to cold chain transportation, especially at
customs; inability to find local laboratory technicians with
molecular biology expertise; and lack of in-country trouble-
shooting and maintenance services.
These findings are not unique to MSF and the two main
implementation barriers to be overcome for facilitating
access to viral load testing in resource-limited settings are
cost and complexity [2]. The development of simpler
laboratory-based tests, or even point-of-care devices, could
therefore go a long way in solving these access problems,
if prices are low enough. Current tests are not considered
suitable for district laboratory settings because they are
expensive and technically complex, requiring a large labora-
tory area and highly trained staff.Two exceptions may be the
ExaVir Load Assay, a non-molecular, ELISA-based technique,
and the Generic HIV-1 Viral Load Assay (Biocentric, Bandol,
France), which has been developed by the Agence Nationale
de Recherches sur le SIDA et les hepatites virales (ANRS) for
resource-limited settings and has a small laboratory footprint
[4147]. Both tests may be performed at district laboratory
level and are less costly than their counterparts, but still rely
on medium to highly trained technicians [3841].
There is a pipeline of devices that, if shown to be
technically validated, cost-effective and field appropriate,
will greatly enhance our ability to implement viral load
testing in a decentralized approach, at point of service. The
first products are predicted to be available from 2013. These
include greatly simplified laboratory-based tests that can be
used at district level, or in mini-laboratories set up alongside
public health clinics, and automated, all-in-one, point-of-care
tests that can be used at the clinic level by clinicians or even
lay workers. A review of the pipeline has recently been
published and will not be considered further here [48].
A number of operational challenges will have to be
overcome during the implementation of these new devices,
including the cost-effectiveness compared to centralized
laboratory-based testing; the ability to meet through-put
requirements; the effect on health service outcomes, such as
staff work-load at the clinics, and number of transcription
errors; and the effect on patient outcomes (morbidity,
mortality and retention in care). In addition, staff should
be adequately trained to acquire the appropriate sample
and operate the instruments correctly, and strict quality
control should be mandatory, even at decentralized facilities
[3949].
Options for roll-out of routine viral load may be considered
in three tiers: (1) a centralized high through-put approach
utilizing traditional platforms paired with DBS as a sample
transport method; (2) simple, automated devices at district
laboratory level; and (3) true point-of-care devices at
individual clinic level. The choice will depend on the
individual programme setting, cohort size, and whether the
epidemic is generalized or concentrated. Where a decentra-
lized approach to ART provision is implemented, careful
consideration needs to be given to through-put require-
ments, feasibility of ensuring quality control and the cost-
effectiveness of a true point-of-care test. These should be
balanced against the need for an effective specimen collec-
tion and result delivery system in a centralized approach.
Experience of moving CD4 testing for ART initiation from
a centralized laboratory to a point-of-care approach pro-
vides some insights about potential challenges for imple-
mentation of point-of-care viral load testing. Task shifting for
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3performance of the test has proven feasible, with improved
patient retention prior to ART initiation [50,51]. However,
sampling errors have illustrated the importance of adequate
staff training in the implementation of point-of-care CD4
testing [5153].
Approaches to a phased implementation
The benefits of providing routine viral load monitoring in
resource-limited settings were recognized a decade ago [54],
but, with the exception of South Africa and Botswana,
widespread access to routine viral load testing in Africa is
still a long way off. Nevertheless, a number of approaches
have been recently piloted to support the WHO recommen-
dation to phase in viral load testing. These are discussed in
the subsequent sections.
Dried blood spots
The sensitivity of molecular viral load testing is dependent
on the volume of sample, and 1ml of plasma is usually
recommended to achieve a sensitivity down to 50 viral
copies/ml. The disadvantages of using plasma as a sample
type are that whole venous blood must be drawn by a health
professional and plasma must be separated from the whole
blood within six hours of blood draw [40]. This is both
impractical and unreliable in remote settings that are far
from laboratories or where the clinics do not have a daily
transport network for samples. Transportation of samples, in
particular, remains one of the biggest challenges to viral load
testing in resource-limited settings. One solution is to use
DBS [55], where whole blood is pipetted onto filter paper,
which is then stored, with desiccant, in an air-tight bag [42].
Whole blood may be taken from a finger or heel prick, for
example, by trained lay workers.This overcomes the need for
clinical staff or phlebotomists, and desiccated filter papers
may be transported easily over long distances, without the
need for a cold-chain or speedy delivery, with elution of
the nucleic acid from the filter paper being the only extra
laboratory step [40,42]. The preparation of DBS is commonly
used in resource-limited settings as a sample type for early
infant diagnosis and is therefore a familiar and well-
established technique [42,56]. Genotypic resistance testing
may also be performed from DBS [46].
There are two potential disadvantages to DBS. First, the
small sample volume (50 to 100ml) results in poor sensitivity
at lower viral loads below 3000 viral copies/ml [42,45],
making it difficult to use a threshold of 1000 copies/ml to
reliably diagnose virological failure [57]. Second, the use of
whole blood rather than plasma means that pro-viral DNA
and cellular RNA are amplified along with plasma viral RNA,
artificially raising the viral load at lower values below
5000 copies/ml [58]. The latter may lead to a false diagnosis
of virological failure with adverse clinical implications. The
only technique currently available that is RNA specific is the
NASBA technique, used in the NucliSENS Assay [42]. Alter-
natively, a DNAse pre-step, or DNase-containing filter paper,
may be used to select for RNA [59]. Thus, the limits of DBS-
based virological testing may be overcome by (1) raising
the threshold for virological failure to 3000 copies/ml and
(2) using RNA-specific techniques that select for viral RNA so
that pro-viral DNA contamination may be avoided.
Pooled viral load testing
Pooled sample testing is a strategy to reduce the number of
samples run by combining five to ten samples together
[6062]. If the pooled sample tests positive, an algorithm is
then used to identify those individuals with a detectable viral
load, or, failing this, the individual samples in the pool are
tested individually. When less than a third of patients are
viremic, negative predictive values are 100% at viral loads
above 500 copies/ml.
Pooled viral load testing can reduce the number of
individual tests required by up to 60%, without compromis-
ing on accuracy. Cost savings are significant, with one study
from Mexico quoting a saving of up to $14,308 by a 30%
reduction in individual testing [60], a study in San Diego
reporting a 70% cost saving from an almost 50% reduction in
individual testing [61] and a study in South Africa reporting a
$1220 per 100 specimens (at $40 per test) saving from a
30% reduction in individual testing [62].
Reducing testing frequency
A recent costing study assessing the cost-effectiveness of
viral load compared to CD4 testing determined that the cost-
effectiveness of viral load testing was sensitive to the
frequency of testing, with annual viral loads being more
cost-effective than the currently recommended six-monthly
viral load testing [63]. Currently,WHO guidelines recommend
viral load testing every six months [16] but, in practice,
testing frequency varies. In Malawi, viral load testing is
recommended to be performed every two years, whereas
in South Africa it is done annually. Another study, from
South Africa, that assessed the optimal timing of viral load
testing concluded that viral load testing done at three
months post-ART initiation is associated with better out-
comes than viral load testing performed at six months [24].
These results suggest that an initial viral load is beneficial for
detecting early adherence problems. After this initial phase,
once patients have adapted to taking ARTand reached stable
and durable viral suppression, less frequent viral load testing
may be possible. Future research is needed in this regard.
Replacing immunological monitoring with virological
monitoring
Clinical trials conducted so far have only assessed the added
value of viral load monitoring, rather than evaluating the
potential to use viral load testing to replace CD4 as a patient-
monitoring strategy [57]. Future trials should consider
comparing CD4 and viral load monitoring head-to-head,
following patients for longer duration, so that the possibility
of abandoning immunological monitoring may be considered.
Further evidence is required to assess the benefit of CD4
monitoring above and beyond viral load, following baseline
CD4 at initiation (including for patients who develop clinical
problems and to guide decisions about cotrimoxazole or
fluconazole prophylaxis).
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4Prioritizing patients for viral load
Even with the many potential opportunities for simplifying
the provision and reducing the cost of viral load testing, roll
out at national level may still need to be phased in. Scale up
of a triggered viral load testing approach using a clear
algorithm to identify patients with CD4 reductions of 30% or
more, specific clinical signs and those with poor adherence
may be one approach. The MSF programme in Zimbabwe,
recognizing a severe under-detection of treatment failure in
their setting, implemented such an algorithm and saw a
substantial increase in the number of viral load tests
requested and subsequent detection of cases eligible for
second-line ART. Alternative approaches, where routine viral
load testing may not yet be feasible, may include the
introduction of viral load testing to assess early adherence,
continuing subsequent monitoring with CD4; as a tool to
detect virological failure prior to switching to a less toxic first-
line regimen; to confirm treatment failure before switching
to second-line ART; or to monitor ARV-treated pregnant
women before birth and during breast-feeding to confirm
viral suppression. Introducing viral load in such a phased
manner may allow for the logistical and technical laboratory
capacity to be firmly established before scaling up the service
to support routine virological monitoring for all.
Discussion
Routine virological monitoring for HIV-positive patients on
ART is important for early detection of virological failure,
preventing the development of drug-resistant mutations,
identifying patients in need of intensive adherence support
and accurately diagnosing treatment failure. Through these
clinically advantageous outcomes, the use of first-line drugs
may be preserved and transmission of viral strains that are
both drug sensitive and drug resistant may be limited.
Use of viral load testing may facilitate task shifting and
reduce the number of clinical visits required for the patient.
A once yearly viral load test could be the only treatment
efficacy monitoring test required, which, if undetectable,
allows for a simplified follow-up of patients on ART through
community-based models, in line with the current priorities
of the WHO [64].
Despite clear benefits, virological monitoring, especially on
a routine basis, is the exception in resource-limited settings.
It is therefore important for both national and international
guidelines to clearly recommend routine virological monitor-
ing for all patients on ART as the standard of care and for
donors and governments to fund the implementation of
accurate and operationally proven testing platforms in a
comprehensive manner. Importantly, operational research
will be required to investigate which tests work better at
different levels of the healthcare system and in different
settings.
The implementation of point-of-care viral load testing will
need to be accompanied by operational research to deter-
mine which system, or combination of systems, work best in
which contexts. Further simplification of laboratory-based
tests, so that they can be performed at district level, will
allow for the decentralization of testing currently performed
at national level and should thus be prioritized.
Ultimately, the price of viral load testing will have to be
reduced to benefit the majority of patients in need.There are
currently only four main suppliers of single-manufacturer viral
load testing platforms, and just one of those has a majority
stake in Africa [48]. These four platforms are expensive,
require a high level of technical skill and laboratory infra-
structure, and are more suited to national or reference
laboratories. A broader availability of tests capable of being
placed at district laboratory and clinic level, without the
formation of a monopoly by a single manufacturer, is there-
fore required. Going forward, it will be important to ensure
that multiple manufacturers are able to enter what will be a
growing market for viral load testing and that incentives for
manufacturers of quality-approved generics are encouraged
through mechanisms, such as cooperative licensing strategies,
that will enable access to the large number of overlapping
patents applicable to molecular techniques [65]. Simplifica-
tion of testing along with price-reducing strategies is needed
to support full implementation of viral load monitoring in
remote and resource-limited settings.
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